



Health innovation that matters

U.S. Securities and Exchange Commission  
100 F Street N.E.  
Washington, D.C. 20549

March 1, 2022

Re: Notice of Disclosure Filed in Exchange Act Quarterly Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934

Ladies and Gentlemen:

Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that LivaNova PLC has made disclosure pursuant to those provisions in its Annual Report on Form 10-K for the period ended December 31, 2021, which was filed with the Securities and Exchange Commission on March 1, 2022. The disclosure can be found within Part I, Item 1. *Business* in the Annual Report on Form 10-K.

Respectfully submitted,

LivaNova PLC

By: /s/ DAMIEN MCDONALD  
Damien McDonald  
Chief Executive Officer

By: /s/ ALEX SHVARTSBURG  
Alex Shvartsburg  
Chief Financial Officer